Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice

Gut

Volumn 59, Issue 2, 2010, Pages 186-196

  Jin, Xiaoling ^a   Zimmers, Teresa A ^a   Zhang, Zongxiu ^a   Pierce, Robert H ^b   Koniaris, Leonidas G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CASPASE; FLICE INHIBITORY PROTEIN; FLUOROURACIL; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL FUNCTION; CELL LABELING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CRYPT CELL; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; EPITHELIUM HYPERPLASIA; FEMALE; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE FUNCTION; INTESTINE INJURY; INTESTINE ISCHEMIA; INTESTINE RESECTION; INTESTINE VILLUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REPERFUSION; WILD TYPE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; ENTEROCYTES; HYPERTROPHY; INTERLEUKIN-6; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; REPERFUSION INJURY; STAT3 TRANSCRIPTION FACTOR;

EID: 77149154988     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.151175     Document Type: Article

References (37)

1. Sukhotnik I, Siplovich L, Krausz MM, et al. Peptide growth factors and intestinal adaptation in short bowel syndrome. Isr Med Assoc J 2003;5:184-7.
2. Ukleja A, Scolapio JS, Buchman AL. Nutritional management of short bowel syndrome. Semin Gastrointest Dis 2002;13:161-8.
3. Martin GR, Beck PL, Sigalet DL. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol 2006;12:4117-29.
4. Jeppesen PB. The use of hormonal growth factors in the treatment of patients with short-bowel syndrome. Drugs 2006;66:581-9.
5. Cisler JJ, Buchman AL. Intestinal adaptation in short bowel syndrome. J Investig Med 2005;53:402-13.
6. McClane SJ, Rombeau JL. Cytokines and inflammatory bowel disease: a review. JPEN J Parenter Enteral Nutr 1999;23:S20-4.
7. Jin X, Zimmers TA, Perez EA, et al. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 2006;43:474-84.
8. Klover PJ, Zimmers TA, Koniaris LG, et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784-9.
9. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6 dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278:13740-6.
10. Sun Z, Klein AS, Radaeva S, et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003;125:202-15.
11. Giraud AS, Jackson C, Menheniott TR, et al. Differentiation of the gastric mucosa IV. Role of trefoil peptides and IL-6 cytokine family signaling in gastric homeostasis. Am J Physiol Gastrointest Liver Physiol 2007;292:G1-5.
12. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-5.
13. Zimmers TA, McKillop IH, Pierce RH, et al. Massive liver growth in mice induced by systemic interleukin 6 administration. Hepatology 2003;38:326-34.
14. Zimmers TA, Pierce RH, McKillop IH, et al. Resolving the role of IL-6 in liver regeneration. Hepatology 2003;38:1590-1.
15. Jin X, Zhang Z, Beer-Stolz D, et al. Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology 2007;46:802-12.
16. Koniaris LG, Zimmers-Koniaris T, Hsiao EC, et al. Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration. J Immunol 2001;167:399-406.
17. Hart ML, Ceonzo KA, Shaffer LA, et al. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol 2005;174:6373-80.
18. Falcone RA Jr, Shin CE, Erwin CR, et al. The adaptive intestinal response to massive enterectomy is preserved in c-SRC-deficient mice. J Pediatr Surg 1999;34:800-4.
19. Tang Y, Swartz-Basile DA, Swietlicki EA, et al. Bax is required for resection-induced changes in apoptosis, proliferation, and members of the extrinsic cell death pathways. Gastroenterology 2004;126:220-30.
20. Zhang HM, Rao JN, Guo X, et al. Akt kinase activation blocks apoptosis in intestinal epithelial cells by inhibiting caspase-3 after polyamine depletion. J Biol Chem 2004; 279:22539-47.
21. Zhou H, Li XM, Meinkoth J, et al. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 2000;151:483-94.
22. Kim AH, Khursigara G, Sun X, et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001;21:893-901.
23. Franke TF, Hornik CP, Segev L, et al. PI3K/Akt and apoptosis: size matters. Oncogene 2003;22:8983-98.
24. Taub R, Greenbaum LE, Peng Y. Transcriptional regulatory signals define cytokine-dependent and -independent pathways in liver regeneration. Semin Liver Dis 1999;19:117-27.
25. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 2003;112: 978-80.
26. Koniaris LG, McKillop IH, Schwartz SI, et al. Liver regeneration. J Am Coll Surg 2003;197:634-59.
27. Montero-Julian FA. The soluble IL-6 receptors: serum levels and biological function. Cell Mol Biol (Noisy-le-grand) 2001;47:583- 97.
28. Wehner S, Schwarz NT, Hundsdoerfer R, et al. Induction of IL-6 within the rodent intestinal muscularis after intestinal surgical stress. Surgery 2005;137: 436-46.
29. Hang CH, Shi JX, Li JS, et al. Expressions of intestinal NF-kappaB, TNF-alpha, and IL-6 following traumatic brain injury in rats. J Surg Res 2005;123:188-93.
30. Brozek W, Bises G, Girsch T, et al. Differentiation- dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur J Cancer 2005;41:2347-54.
31. Rollwagen FM, Madhavan S, Singh A, et al. IL-6 protects enterocytes from hypoxia-induced apoptosis by induction of bcl-2 mRNA and reduction of fas mRNA. Biochem Biophys Res Commun 2006;347:1094-8.
32. Wang W, Smail N, Wang P, et al. Increased gut permeability after hemorrhage is associated with upregulation of local and systemic IL-6. J Surg Res 1998;79:39-46.
33. Wang Q, Sun X, Pritts TA, et al. Induction of the stress response increases interleukin-6 production in the intestinal mucosa of endotoxaemic mice. Clin Sci (Lond) 2000;99:489-96.
34. Kimizuka K, Nakao A, Nalesnik MA, et al. Exogenous IL-6 inhibits acute inflammatory responses and prevents ischemia/reperfusion injury after intestinal transplantation. Am J Transplant 2004;4:482-94.
35. Tebbutt NC, Giraud AS, Inglese M, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002;8:1089-97.
36. Cui Z, Willingham MC, Hicks AM, et al. Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci U S A 2003;100:6682-7.
37. Jenkins BJ, Grail D, Nheu T, et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 2005;11:845-52.